Navigation Links
Breckenridge Pharmaceutical Enters Agreement With Helm AG (Hamburg, Germany) to Develop Additional ANDA Project
Date:4/1/2008

BOCA RATON, Fla., April 1, 2008 /PRNewswire/ -- Breckenridge announced today that it has entered into another separate agreement with Helm AG to develop and manufacture a generic ANDA product. Under terms of this new agreement, Breckenridge will submit an ANDA to the U.S. Food and Drug Administration (FDA) for the product which will be developed by Helm AG. The product currently shows U.S. sales of approximately $279 million, and is patent protected until 2011.

The two companies previously announced plans to develop and manufacture a generic tablet ANDA product in December 2007. The product was recently filed with the U.S. Food and Drug Administration (FDA).

About Breckenridge:

Breckenridge Pharmaceutical is a privately held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of ValuBrand(TM) and Generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 100 products, more than 150 sku's, in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions and Topical preparations. http://www.bpirx.com

About Helm AG:

HELM AG is an international chemical and pharmaceutical organization and a multifunctional marketing group which operates as a link between producers and industrial end users. With branch offices and participations in 32 countries HELM provides a wide range of services including marketing, distribution, production, logistics, generic development and registration. http://www.helmag.com


'/>"/>
SOURCE Breckenridge Pharmaceutical
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Breckenridge Pharmaceutical Signs Long Term Agreement with Helm AG (Hamburg, Germany)
2. Breckenridge Pharmaceutical Settles Paragraph IV Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 23, 2017 , ... Texas Home Health, an ... two personal care service companies: Padre Home Health in Corpus Christi, Texas, and ... , Well regarded in their respective markets, these two agencies align with Texas ...
(Date:1/24/2017)... Clara, CA (PRWEB) , ... January 23, 2017 ... ... announces the launch of a new plugin that allows sleep centers to automatically ... Sleep Device Interface (SDI)—is a thin client browser plugin is quickly installed on ...
(Date:1/23/2017)... ... January 23, 2017 , ... PKF O’Connor Davies ... J. Nelson, a senior accountant at the Firm, will participate in the 40th Annual ... Over 200 runners will race up 1,576 steps, a vertical distance equal to about ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... the highly acclaimed series, Innovations with Ed Begley, Jr., scheduled to broadcast Saturday, ... technology behind SmartCap, which was founded in 2008 to address the limitations of ...
(Date:1/23/2017)... ... January 23, 2017 , ... The Masters ... management and evaluation leaders with decades of experience who remain current practitioners in ... States healthcare system, there is a renewed demand for versatile, data-driven leadership.The American ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... The global peripheral I.V. catheter market accounted for $3,702.2 ... grow at a CAGR of 6.0% during 2016-2022. The ... in the global market between the two types in ... segment accounted for the highest share in the global ... catheter market is witnessing high growth rate, due to ...
(Date:1/24/2017)... CHICAGO , January 23, 2017 ... solutions for life sciences, announces agClinical 3.3, the latest ... release further enables life science organizations to confidently and ... monitoring and better manage the electronic trial master file ... ...
(Date:1/23/2017)... , Jan. 23, 2017  HOPE BIOSCIENCES announced ... to develop and commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) ... Korean pharmaceutical company. nuc -Gemcitabine ... against surface nucleolin found on many cancer cells, ... ADCs (antibody drug conjugates) or SMDCs (small molecule ...
Breaking Medicine Technology: